Finding ways to overcome treatment resistance in aggressive breast cancer
Overcoming chemoresistance in triple negative breast cancer
['FUNDING_R01'] · MEDICAL UNIVERSITY OF SOUTH CAROLINA · NIH-10994079
This study is looking at a tough type of breast cancer called triple negative breast cancer (TNBC) and is exploring how a protein named lysyl oxidase (LOX) makes it harder for chemotherapy to work, with the goal of creating new treatments that can help these tumors respond better to medication.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MEDICAL UNIVERSITY OF SOUTH CAROLINA (nih funded) |
| Locations | 1 site (CHARLESTON, UNITED STATES) |
| Trial ID | NIH-10994079 on ClinicalTrials.gov |
What this research studies
This research focuses on triple negative breast cancer (TNBC), a particularly aggressive form of breast cancer that often does not respond well to standard chemotherapy. The team is investigating a protein called lysyl oxidase (LOX), which has been found to contribute to resistance against chemotherapy drugs like doxorubicin. By understanding how LOX works and developing specific inhibitors to block its activity, the researchers aim to make TNBC tumors more responsive to treatment. This approach involves studying the mechanisms of LOX in the tumor environment and testing new drug prototypes in laboratory models.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have experienced resistance to chemotherapy.
Not a fit: Patients with non-triple negative breast cancer or those who have not undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with triple negative breast cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
CHARLESTON, UNITED STATES
- MEDICAL UNIVERSITY OF SOUTH CAROLINA — CHARLESTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SAHIN, OZGUR — MEDICAL UNIVERSITY OF SOUTH CAROLINA
- Study coordinator: SAHIN, OZGUR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: aggressive breast cancer